News

The settlement is expected to close by September 5, 2008. UCB will pay Eurand a total of $35 million, of which $25 million will be paid at closing,

This finding is from a subanalysis designed and completed following the closure of the five-year treating to new targets (TNT) study in patients with existing coronary heart disease.

This is said to be the first application submitted by Scolr based on its controlled delivery technology platform. Pseudoephedrine is an active ingredient in Allegra D, Sudafed PSE,

Under the agreement, Covance will acquire Lilly’s 450-acre early drug development campus in Greenfield, Indiana for $50 million and will offer employment to about 260 Lilly employees. In

The Alnylam product candidate, ALN-VSP, is being developed as a treatment for liver cancers and potentially other solid tumors. ALN-VSP comprises small interfering RNA (siRNA) molecules delivered systemically

The open-label, multi-dose, dose-escalation Phase I clinical trial is expected to enroll up to 46 patients with selected advanced or recurrent solid tumors. This trial is designed to

According to the company, DXLr120 significantly improves antibodies binding to CD20, the target for non Hodgkin’s lymphoma and rheumatoid arthritis and joins InNexus’s DXL625 (CD20). DXL625, developed with

Bernd Seizinger, CEO of GPC Biotech, said: “We are disappointed, but we understand Celgene’s decision given their recent withdrawal of the marketing authorization application for satraplatin in Europe.

Since 2001, Lilly has utilized Phase Forward’s InForm product in over 200 trials and plans to continue to use InForm for global trials across all phases, as well